ORIX finalises Greenko share transfer deal
This move by ORIX follows an initial agreement terminated in April 2025 due to unmet conditions.
The transaction includes the partial sale of shares in India-based renewable energy firm Greenko and an investment in convertible notes issued by AMG Lux, the parent entity holding all shares of AMG.
Regulatory approvals under the Indian Competition Act have been obtained.
ORIX plans to close the partial transfer of Greenko shares and the guaranteeing of the convertible notes by end-July 2025.
Greenko has an installed capacity of 7.3GW across solar, wind and hydroelectric power generation facilities in India, and is developing large-scale pumped storage power generation projects.
The strategic divestment from Greenko aligns with ORIX's capital recycling strategy as they aim to reinvest funds into expanding sectors such as green molecules that contribute towards global decarbonisation efforts.
AMG was founded by Anil Chalamalasetty and Mahesh Kolli who are also behind the establishment of Greenko.
It focuses on developing green hydrogen and ammonia production projects alongside water electrolysis equipment manufacturing essential for green hydrogen production.
AMG plans to produce five million tonnes per annum (mtpa) of green ammonia through its various projects.
The initial project with a capacity of 1mtpa is under construction in Kakinada, Andhra Pradesh, India, with commissioning set for the second half of 2026.
Binding term sheets have been signed by AMG with companies such as Uniper and Yara Clean Ammonia to supply green ammonia to Europe.
Renewable energy remains central to ORIX's strategic growth areas as it continues expanding globally through solar, wind and geothermal power.
ORIX acquired Elawan Energy, headquartered in Spain – a wholly-owned entity within the group portfolio currently managing 4.7GW worldwide capacity.
In December 2024, the Greenko Group contracted AFRY to deliver comprehensive design engineering services for a 1.8GW Shahpur pumped hydro energy storage project in Rajasthan, India.
"ORIX finalises Greenko share transfer deal" was originally created and published by Power Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
OpenRock S2 Debuts -- Ultra-Light Open-Ear Sports Earbuds Engineered for Comfortable Fit
HONG KONG, July 1, 2025 /PRNewswire/ -- OpenRock, an industry-leading open-ear audio brand, officially launches the OpenRock S2, ultra-light open-ear sports earbuds. Weighing just 7 grams each, it features a secure and lightweight design that delivers high-quality audio while keeping you aware of your surroundings. It has earned praise worldwide from well-known media outlets such as Android Headlines and NeozOne. Key features include: 7g Ultra-Light Hook-Clip Design: Each earbud weighs just 7g, combining an ultra-thin 0.6mm titanium wire and soft liquid silicone for a flexible fit. The ergonomic hook-clip design ensures even pressure distribution for a secure and all-day comfort. Triple Sweat & Water Protection: An angled fit channels sweat away, allowing it to naturally slide off. The independent cavity and waterproof nano-coating protect the internal components. With IPX5 water resistance, it stands up to sweat and light rain with ease. Premium Sound with BassDirect™: The BassDirect™ technology delivers deep, low-distortion bass. Enhanced by the LISO 2.0 algorithm, LDAC codec, and Hi-Res Audio certification, the OpenRock S2 ensures clear, high-fidelity sound. Remote Camera Control: Easily snap photos or start recording videos by pressing the earbud button four times when your phone is in photo or video mode—ideal for hassle-free shooting on the go. Up to 32-Hour Battery Life: Enjoy up to 8 hours on a single charge, and up to 32 hours with the charging case. A 5-minute quick charge provides 1 hour of playback. OpenRock is dedicated to providing an exceptional auditory experience through superior craftsmanship and sound quality. Its innovative open-ear air-conduction design delivers "The Sound of Freedom" – rich bass and clarity – while keeping wearers aware of their surroundings. By seamlessly blending functionality with cutting-edge technology, OpenRock earbuds enable users to enjoy immersive sound—whether they're pursuing an active lifestyle or simply enjoying their favorite music throughout the day. The OpenRock S2 was officially launched on July 1, 2025, at a retail price of $98.99. It is now available for purchase globally via the official OpenRock website and Amazon. View original content to download multimedia: SOURCE OpenRock Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
This Chinese Stock Just Launched Something That Could Be Even Bigger and More Powerful Than DeepSeek
Baidu (BIDU) shares are in focus after the company made its ERNIE large language models (LLMs) open source – effectively enabling the global AI community to use them for R&D. Note that Baidu's ERNIE 4.5 series outperforms DeepSeek's V3 model on a significant number of benchmarks across key capability categories. Elon Musk's Tesla Makes History With 'First Time That a Car Has Delivered Itself to Its Owner' This Defense Stock Could Be the Next Palantir. Should You Buy It Now? Cathie Wood Is Pounding the Table on AMD Stock. Should You Buy Shares Now? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Still, Baidu stock is down some 19% versus its year-to-date high at the time of writing. Baidu shares stand to benefit rather significantly from management's decision to open source ERNIE models. By making its LLMs freely available under the Apache 2.0 license, BIDU invites global developers to build, fine-tune, and deploy on its architecture – accelerating adoption and ecosystem growth. Baidu's move mirrors the success of DeepSeek's open-source strategy, which reshaped China's AI landscape. The open-source release also enhances transparency and trust – potentially attracting enterprise and government partnerships. In short, the announcement positions BIDU as a foundational platform – a shift that could unlock long-term monetization and valuation upside. Baidu stock hasn't been particularly exciting for investors this year, but Miranda Zhuang – a Bank of America analyst – recommends owning it for the long term. Zhuang is bullish on BIDU shares primarily because the Beijing-headquartered firm has already launched fully autonomous vehicle operations in China. Moreover, Baidu is fully committed to expanding its robotaxi services internationally, which she's convinced will drive incremental revenue growth in the years ahead. Integrating artificial intelligence will help BIDU reinvigorate growth in its advertising business as well, according to the BofA analyst. Miranda Zhuang currently has a 'Buy' rating on Baidu shares and a price target of $100, indicating potential upside of another 18% from here. Other Wall Street firms also expect BIDU shares to extend gains as the Chinese tech behemoth continues to tap on artificial intelligence in pursuit of lower costs and higher returns. At the time of writing, the consensus rating on Baidu stock sits at 'Moderate Buy' with the mean target of about $105 indicating potential upside of some 22% from current levels. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Biosimilars Market Size to Hit $76.2 Billion by 2030 - Driving Value-Based Care for Drugmakers, Regulators & Emerging Markets
CHICAGO and PUNE, India, July 1, 2025 /PRNewswire/ -- What's Fuelling the US$76.2 Billion Biosimilars Market? The Global Biosimilars Market size is projected to be valued at USD 27.20 billion in 2023 and reach USD 76.20 billion by 2030, growing at a CAGR of 15.9% according to a new report by The Research Insights. This growth is driven by several key factors, including a rising number of regulatory approvals and product launches, the patent expiries of major biologics, and the increasing prevalence of chronic diseases that require effective and affordable treatment options. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the Biosimilars Market growth of 15.9% comprises a vast array of product, application and geography which are expected to register strength during the coming years. For More Information and To Stay Updated on The Latest Developments in The Global Biosimilars Market Size, Download FREE Sample Pages: Why Are Biosimilars Emerging as the Backbone of Affordable Biologic Therapies? According to an exhaustive report by The Research Insights, the Biosimilars Market is experiencing significant growth. The rapidly evolving global pharmaceutical industry is characterized by several unique and trending factors contributing to shaping the current landscape and competitive dynamics of the biosimilars market. The key factors include the increasing demand for affordable biologic therapies driven by the rising healthcare expenditures and the burgeoning prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes across the globe. The impending or already occurred patent expiries of several blockbuster biologics drugs have created a conducive environment for biosimilar manufacturers, opening the market to more competition and new entrants at an accelerated rate. Additionally, the establishment of supportive regulatory frameworks and streamlined approval pathways in key markets such as the United States, European Union, and emerging economies, is enabling the fast-paced development and acceptance of biosimilars. Furthermore, growing awareness, education, and positive experience among physicians and patients is also contributing to a greater acceptance and adoption of biosimilars by effectively reducing the resistance to switching from reference products. The enhanced technological advancements in biologic drug manufacturing and analytical characterization are also driving down the cost of production while maintaining the high quality of biosimilar products. Collaborative efforts and strategic partnerships among key players such as biopharma companies, Contract Development and Manufacturing Organizations (CDMOs), and supportive government initiatives to increase the access to affordable biologics are also playing a vital role in facilitating the growth of the biosimilars market. Some of the other trends observed in the biosimilars space, which are set to influence the competitive dynamics, include the incorporation of digital health platforms, personalized medicine, and the application of artificial intelligence in biosimilar development. What Role Do Patent Expirations and Budget Constraints Play in the Biosimilars Boom? The loss of patents and exclusivity rights of several key biologic drugs is a major driver of the biosimilars market. Many of the high-cost, blockbuster biologic drugs such as Humira (adalimumab), Remicade (infliximab), Herceptin (trastuzumab), Enbrel (etanercept), etc., have already lost their patents or are about to, which has paved the way for the entry of biosimilar versions in the market. As biologics are some of the highest spending drugs across the globe, and since many of these medications are used for the treatment of chronic and complex diseases, such as cancer, rheumatoid arthritis, inflammatory bowel disease, diabetes, etc., healthcare systems are actively looking for more cost-effective alternatives to the originator products. In addition, biosimilars help in reducing the costs of expensive biologics, which often represent a major share of national drug budgets, and insurers' spending. Biosimilars typically provide a cost-saving alternative at 15–30% less expensive than the originator biologic products, while also assuring similar safety and efficacy profiles as demonstrated in head-to-head trials. This increased price competition helps in reducing the financial burden of these specialty drugs on the national healthcare systems, the health insurers, and the patients and thus will encourage faster uptake and deeper market penetration. For Detailed Market Insights, Visit: How Are Chronic Disease Burdens and Biologic Demand Powering the Biosimilars Market?The surging global burden of chronic and lifestyle-related diseases, such as cancer, autoimmune disorders, and diabetes, has led to the high demand for biologic therapies and subsequently for their biosimilar versions as well. Biologics are fast becoming the standard of care for many diseases for which either the existing therapies are not very effective, or patients do not respond to them adequately. However, their high cost can be a major barrier to the use of these biologic therapies, especially in low- and middle-income countries. Biosimilars present an excellent opportunity to address this unmet need by improving access to lifesaving medicines at reduced prices. Given the demographic shift toward the older population and the concomitant increase in the incidence of chronic diseases around the world, the demand for biosimilars is expected to grow at a much faster pace, especially in oncology, endocrinology, and immunology therapeutic areas, in the coming years. This is also further corroborated by the fact that healthcare providers and policy decision-makers are looking for cheaper ways to manage therapies for long-term diseases. Are Governments and Payers Creating the Perfect Storm for Biosimilar Expansion? The establishment of streamlined and accelerated regulatory pathways for biosimilars in key global markets, such as the U.S. FDA's Biologics Price Competition and Innovation Act (BPCIA) and the EMA's well-defined and established biosimilar guidelines, have also been key factors propelling the growth of this space. The approval requirements for biosimilarity, interchangeability, labeling, and pharmacovigilance have been clearly defined by the respective regulatory authorities, which will in turn increase the confidence of physicians, pharmacists, and patients in using biosimilars. In addition, several countries and health insurance providers have introduced supportive policies and strategies to promote the use of biosimilars over biologic originators, such as substitution laws, tendering, and reimbursement policies. For instance, countries such as Germany, the UK, and Norway have witnessed a significant uptake in biosimilar products due to national incentive programs, recommendations for substitution, and mandatory switching policies. Such policy support not only helps lower the entry barriers for the manufacturers and increase the safety and efficacy of biosimilar products, but also builds greater market confidence, which will in turn provide a favourable environment for greater adoption of biosimilars. Stay Updated on The Latest Biosimilars Market Trends: Where Is Biosimilar Adoption Accelerating Fastest—and Why Now? North America has long held its ground as the dominant regional player in the global biosimilar market, accounting for 40.4% of the total revenue generated in this Pacific is anticipated to exhibit a Compound Annual Growth Rate (CAGR) of 18.4% during the forecast period. The presence of key players such as Dr. Reddy's Laboratories, Biocon, Pfizer Inc., and Celltrion, has significantly influenced the development and commercialization of biosimilars in the region. How Are Product, Application, and Regional Dynamics Shaping the Global Biosimilars Market Landscape? Based on Product, the biosimilars market is divided into, Recombinant Non-glycosylated Proteins, and Recombinant Glycosylated Proteins. The recombinant non-glycosylated proteins segment led in terms of revenue share, accounting for approximately 54.9%. Based on Application, the biosimilars market is divided into, Oncology, Blood Disorders, Growth Hormonal Deficiency, Rheumatoid Arthritis, Chronic and Autoimmune Disorders, and Others. The segment that accounts for the largest share in terms of revenue is the chronic and autoimmune disorders category, accounting for around 21.6% of the market's total. The Biosimilars Market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Purchase Premium Copy of Global Biosimilars Market Size and Growth Report (2023-2030) at: Which Companies Are Defining the Biosimilars Landscape—and What's Powering Their Momentum? The Global Biosimilars Market is characterized by the presence of several major players, including: Amgen Inc. F Hoffman-La Roche Ltd. Sandoz International GmbH Dr. Reddy's Laboratories Ltd. Teva Pharmaceutical Industries Ltd. Pfizer Inc. Samsung Biopis Biocon Viatris Inc. Celltrion Healthcare Co.,Ltd. AbbVie Inc. These companies are adopting strategies such as new product launches, joint ventures, and geographical expansion to maintain their competitive edge in the market. What's Driving Innovation in the Global Biosimilars Market Today? In April 2025, Sandoz entered into a collaboration with Shanghai Henlius Biotech to commercialize a biosimilar of ipilimumab, a leading oncology therapy to treat certain types of cancers like colorectal cancer, esophageal cancer, hepatocellular carcinoma, malignant pleural mesothelioma, melanoma, non-small cell lung cancer, and renal cell carcinoma. In April 2025, Biocon and Regeneron formed a license agreement to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar to aflibercept, in the US. In April 2025, Biocon Biologics received approval from the US FDA for Jobevne (bevacizumab-nwgd), a biosimilar of Bevacizumab for intravenous use to treat several different types of cancer. In March 2025, Celltrion launched ZYMFENTRA (infliximab-dyyb) across the US market to treat ulcerative colitis (UC) or Crohn's disease (CD). For Region-Specific Market Data, Check Out Brief Sample Pages: Frequently Asked Questions (FAQs): What is the forecasted market size of the Biosimilars Market in 2030?The forecasted market size of the Biosimilars Market is USD 76.20 billion in 2030. Who are the leading players in the Biosimilars Market?The key players in the Biosimilars Market include, Amgen Inc.; FHoffman-La Roche Ltd.; Sandoz International GmbH; Dr. Reddy's Laboratories; Teva Pharmaceutical Industries Ltd; Pfizer Inc.; Samsung Biopis; Biocon; Viatris Inc.; Celltrion Healthcare Co.,Ltd; and AbbVie Inc. What are the major drivers for the Biosimilars Market? Several key factors are propelling this growth, including the increasing number of biosimilar launches and approvals and rising global demand for affordable alternatives to expensive biologic therapies Which is the largest region during the forecasted period in the Biosimilars Market?The North America has long held its ground as the dominant regional player in the global biosimilar market, accounting for 40.4% of the total revenue generated in this space. Which is the largest segment, by product, during the forecasted period in the Biosimilars Market?The recombinant non-glycosylated proteins segment led in terms of revenue share, accounting for approximately 54.9%. Conclusion: The biosimilars market is undergoing a transformation driven by advancements in biotechnology, evolving regulatory landscapes, and expanding manufacturing capabilities. The increasing prevalence of chronic diseases and the rising economic burden on healthcare systems have heightened the demand for affordable and accessible biologic treatments. This demand is driving the accelerated adoption of biosimilars, which are recognized for their clinical efficacy, cost-effectiveness, and improved accessibility. Biosimilars are poised to play a crucial role in broadening patient access to life-saving biologic therapies, especially in oncology, immunology, and endocrinology. The continuous enhancements in analytical characterization, real-world evidence generation, and pharmacovigilance are building confidence in the safety and interchangeability of biosimilars. Strategic collaborations, streamlined regulatory pathways, and supportive policies are propelling market penetration. As the global healthcare landscape shifts towards value-based care, biosimilars are emerging as indispensable components of sustainable healthcare delivery and pharmaceutical innovation. We offer customized research solutions if the above study does not fully align with your specific requirements: The report from The Research Insights, therefore, provides several stakeholders— pharmaceutical companies, healthcare providers, regulatory agencies, patients, payers/insurance companies, and government health authorities—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. With projected growth to US$ 76.20 billion by 2030, the Global Biosimilars Market represents a significant opportunity for, contract manufacturing organizations (CMOs), biotechnology startups, academic research institutions, investment firms, and technology providers can position themselves for success in this dynamic and evolving market landscape. The Critical Questions to be Asking: Rather than "Should we pursue biosimilars?", the strategic questions to be asking are: Which therapeutic areas provide the quickest route to biosimilar profitability in the context of upcoming patent expirations? Where should we build or acquire manufacturing capabilities to scale and meet global demand for biosimilars? How can we position our company as a trusted brand in the biosimilar space in an increasingly price sensitive market? Who should we partner with to effectively manage regulatory complexity and speed to global market access? Why is now the time to invest in biosimilars in order to compete in the changing landscape of chronic disease care and value-based healthcare? Check out more related studies published by The Research Insights: Biosimilar Contract Manufacturing Market: The Global Biosimilar Contract Manufacturing Market is expected to reach at USD 25.73 billion by 2030, according to a new report by The Research Insights. It is projected to expand at a CAGR of 15.9% during the forecast period. The rising prevalence of chronic diseases such as cancer, autoimmune disorders, and diabetes has created a substantial demand for biosimilars, which offer comparable efficacy to their reference biologics while being more cost-effective. Biosimilar Monoclonal Antibodies Market: According to a report by The Research Insights, the growth of the global biosimilar monoclonal antibodies market is driven by several key factors, including the increasing number of monoclonal antibody patent expirations, ongoing innovations in mAb technology, growing demand for cost-effective therapies, and the rising prevalence of chronic and autoimmune diseases such as cancer and rheumatoid arthritis. Browse More related reports on Healthcare Industry Market Reports – About Us: The Research Insights provides thoroughly conducted research which is backed up by real-time statistics and data. Our experts are eager to help you with any information required under the sun. The key to our success is keeping abreast with the markets, industries, and ever-changing consumer trends that matter. Our market research professionals have in-depth knowledge and expertise across various domains that includes IT and Telecom, Emerging Technologies, Consumer Offerings, Manufacturing and Others. We are committed to reviewing the scope and procedure of the research studies that you select and provide you with an accurate guidance in order to assist you in taking the correct business decisions. Contact Us:If you have any queries about this report or if you would like further information, please contact us: Contact Person: Kaushik RoyE-mail: sales@ +1-312-313-8080Blog: Press Release: Latest News: | Logo: View original content: SOURCE The Research Insights
